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Finding Genes for Alcohol-Related
Behaviors and Risk For Alcoholism
The National Institute on Alcohol Abuse and
Alcoholism (NIAAA) solicits research proposals
to identify and characterize genes that con-
tribute to individual susceptibility to alco-
holism and alcohol-related behaviors. This PA
encourages multidisciplinary studies using
advanced genetic and genomics technologies to
find and characterize candidate genes in
humans and animal models. 
Genetic linkage and association studies
have identified many chromosomal regions
and quantitative trait loci (QTL) associated
with complex phenotypes related to alcohol
induced behaviors and/or alcoholism.
However, the large number of genes residing
in those previously identified chromosomal
regions/QTLs remain undefined, due to the
lack of power and sensitivity of previously
available methodology and technology. The
completion of the sequences of the human
and mouse genomes, and the development of
new genomics technologies, have the potential
for rapidly advancing the discovery of genes
associated with alcoholism and alcohol-related
behaviors. 
NIAAA seeks research applications that
will explore and develop innovative computa-
tional, statistical, and molecular approaches to
increase the power of gene discovery. Areas of
emphasis include utilizing advanced technolo-
gies such as high-throughput SNP genotyp-
ing, haplotype pattern mining, admixture
linkage disequilbrium mapping, and DNA
pooling for fine mapping. Currently, haplo-
type maps for both human and mouse
genomes are being developed and these maps
will provide an additional resource for finding
genes. Once fine mapping has further charac-
terized a previously identified QTL or chro-
mosomal region, candidate nucleotide variants
within the locus can be identified. Some
methods that could be used for fine mapping
include high-throughput sequencing, RAGE,
SAGE, DNA microarrays, protein arrays, and
other high-throughput approaches. 
Many genes are predicted to reside within
a QTL, and multiple polymorphisms are like-
ly to be located in both coding and regulatory
regions. Functional tests of candidate genes
are needed to determine if the polymor-
phism(s) or genetic variants are relevant to the
alcohol-induced trait. These tests may include
the development of transgenic animals, such
as BAC and YAC transgenics carrying chro-
mosomal regions that contain large regulatory
sequences. 
This PA specifically seeks applications
that propose human or animal studies to
identify and characterize genes associated
with alcoholism and alcohol-related behav-
iors. Behaviors include alcohol consumption,
tolerance/dependence, sensitivity/sedation,
withdrawal, reinforcement, craving, and
relapse. Genes identified may be used to
develop markers for alcohol vulnerability and
dependence. In addition, these genes may
also be used to identify potential therapeutic
targets and to predict individual responses to
medications that treat alcoholism. Examples
of research areas appropriate to this
announcement include, but are not limited
to: 1) identification and characterization of
genes associated with alcoholism and alcohol-
related behaviors in the chromosomal regions
previously identified in humans or animal
models; 2) identification of genetic variants
(SNPs/haplotpes) of associated with alco-
holism and alcohol-related behaviors among
the different populations, which will have
high potential as targets for developing phar-
macotherapeutic agents; 3) discovery of new
genes associated with alcoholism and alcohol-
related behaviors and determination of func-
tional relevance of the candidate genes and
their polymorphic variants.
This PA will use the NIH R01 and
Exploratory/Developmental Research Grant
(R21) award mechanisms (see http://grants.nih.
gov/grants/guide/pa-files/PA-03-107.html). 
As an applicant, you will be solely respon-
sible for planning, directing, and executing
the proposed project. Applications using the
R21 mechanism may request a project period
of up to two years with a combined budget for
direct costs of up to $275,000 for the two year
period. For example, the applicant may
request $100,000 in the first year and
$175,000 in the second year. The request
should be tailored to the needs of the project.
Normally, no more than $200,000 may be
requested in any single year. 
This PA uses just-in-time concepts. It also
uses the modular as well as the non-modular
budgeting formats see http://grants.nih.gov/
grants/funding/modular/modular.htm.
Specifically, if you are submitting an applica-
tion with direct costs in each year of $250,000
or less, use the modular format. Otherwise
follow the instructions for non-modular
research grant applications. This program does
not require cost sharing as defined in the cur-
rent NIH Grants Policy Statement at http://
grants.nih.gov/grants/policy/nihgps_2001/
part_i_1.htm.
Exploratory/developmental grant support
is for new projects only; competing continua-
tion applications will not be accepted. Two
revisions of a previously reviewed explorato-
ry/developmental grant application may be
submitted as defined in NIH Policy at
http://grants.nih.gov/grants/policy/
amendedapps.htm.
Applications must be prepared using the
PHS 398 research grant application instruc-
tions and forms (rev. 5/2001). The PHS 398
is available at http://grants.nih.gov/grants/
funding/phs398/phs398.html in an interactive
format. For further assistance contact
GrantsInfo, 301-435-0714, email:
GrantsInfo@nih.gov.
Applications submitted in response to this
PA will be accepted at the standard applica-
tion deadlines, which are available at http://
grants.nih.gov/grants/dates.htm. Application
deadlines are also indicated in the PHS 398
application kit.
Applications must be mailed on or before
the receipt dates described at http://grants.
nih.gov/grants/funding/submissionschedule.
htm. The CSR will not accept any application
in response to this PA that is essentially the
same as one currently pending initial review
unless the applicant withdraws the pending
application. The CSR will not accept any
application that is essentially the same as one
already reviewed. This does not preclude the
submission of a substantial revision of an
application already reviewed, but such applica-
tion must include an Introduction addressing
the previous critique. Contact: Lisa A.
Neuhold, Program Director for Genetics,
Genetics and Proteomics Research Branch,
Division of Basic Research, NIAAA, 6000
Executive Boulevard, Suite 402, MSC 7003,
Bethesda, MD 20892-7003 USA, 301-594-
6228, fax: 301-594-0673, email: Lneuhold@
willco.niaaa.nih.gov; Zhaoxia Ren, Program
Director for Human Genetics, Genetics and
Proteomics Research Branch, Division of Basic
Research, NIAAA, 6000 Executive Blvd, Suite
402, MSC 7003, Bethesda, MD 20892-7003
USA, 301-443-5733, fax: 301-594-0673,
email: zren@mail.nih.gov; Q. Max Guo,
Program Director, Genetics and Proteomics
Research Branch, Division of Basic Research,
National Institute on Alcohol Abuse and
Alcoholism, 6000 Executive Blvd, Suite 402,
MSC 7003, Bethesda, MD 20892-7003 USA,
301-443-0639, fax: 301-594-0673, email:
qmguo@mail.nih.gov. Reference: PA No.
PA-03-162
Neuroprotective CNS Barriers in
Neurological Diseases
The goal of this Program Announcement with
set-aside funds (PAS) is to invite applications
for studying the neurobiological and cere-
brovascular mechanisms through which the
neuroprotective blood-brain and blood-csf bar-
riers function in the healthy and diseased adult,
aged and pediatric brain. Blood-Brain Barrier
(BBB) research embodies the true meaning of a
"translational model" of neuroscience wherein
breakthroughs in basic neuroscience are deliv-
ered to the clinic and require an agent delivery
strategy and/or the ability to target specific
areas of the brain. This PAS encourages studies
focused on improving our understanding of the
neuroprotective CNS barriers and enhancing
the effectiveness of drug and gene delivery
strategies for treatment of neurological diseases.
Chief among the challenges to be addressed is
the need to increase our knowledge about the
molecular and cellular biology, cells of origin,
gene and protein expression, and the regional
differences of brain microvascular endothelial
cells and pericytes and their interactions with
adjacent brain cells. 
A major challenge for treatment of most
brain disorders is overcoming the difficulty of
delivering therapeutic agents to specific
regions of the brain. In its neuroprotective
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role, the blood-brain barrier (BBB) functions
to hinder the delivery of many potentially
important diagnostic and therapeutic agents
to the brain. Therapeutic molecules and genes
that might otherwise be effective in diagnosis
and therapy do not cross the BBB into the
brain in adequate amounts. Improving our
knowledge of the molecular and cellular biolo-
gy of the brain microvasculature and their
interactions with surrounding brain cells,
which constitutes the BBB in vivo, could lead
to innovative strategies for drug and gene tar-
geting to injured or disease tissue. Also,
research is needed on the role of the brain
microvasculature in protecting the brain from
toxic agents and how damage to the BBB
leads to long-term neurological toxicity in the
development of many neurological diseases. 
Understanding the basic biology of how
the BBB works under normal and disease con-
ditions across the lifespan may also provide
insight on the integrative function of the
brain. Research focused on cerebrovascular
endothelial cell biology may provide insight
into the "neurovascular unit", a conceptual
model that considers brain function from the
perspective of interactions among blood cells,
endothelium, glia, pericytes, extracellular
matrix and neurons. 
This initiative was identified as the top
research priority of the Brain Tumor Progress
Review Group (PRG). The Stroke Progress
Review Group has also identified neurovascu-
lar research and BBB biology as a high priority
for advancing our understanding of stroke and
brain function. Both Progress Review Groups
are responsive to Congressional requests for
planning in these areas. Also, the National
Institute of Neurological Disorders and Stroke
(NINDS) Neuroscience at the New
Millennium Plan clearly identifies research on
the blood-brain barrier as a scientific priority.
The scientific support for this initiative can be
found in these reports on the NINDS home-
page at http://www.ninds.nih.gov/funding/
neural_environment/index.htm#research
This PAS is intended to achieve a better
understanding of the effects of neurological
disorders on the blood-brain barrier (BBB),
improve our knowledge of BBB biology and
how it may contribute to the initiation and/or
progression of neurological disease over the
lifespan and develop new approaches for tar-
geting the BBB, based on biological considera-
tions, in order to improve drug delivery and
target treatment of one or more such disorders. 
Applications that address gene and pro-
tein expression for microvascular endothelial
cells within normal, aging, and diseased brain
such as gliomas or the ischemic penumbra are
encouraged. Cerebrovascular genomics is con-
sidered a high priority. Because only very
abundant BBB-specific transcripts will be
detected with whole-brain gene microarrays,
cerebrovascular genomics research needs to
start with the initial isolation of brain capillar-
ies from animal or human brain, both normal
and perturbed. Comparison of capillaries from
normal brain and perturbed tissue can help to
elucidate the tissue-specific gene expression.
Pattern-specific tissue expression could pro-
vide the platform for further investigations on
overall brain vascular biology as it pertains to
conditions such as angiogenesis, cell adhesion,
antigen presentation, metastasis, cell-cell com-
munication and local inflammation. 
There are several modalities for drug and
gene delivery through the BBB. They include:
BBB disruption; the use of endogenous trans-
port systems, including carrier-mediated
transporters such as glucose and amino acid
carriers; receptor-mediated transcytosis, sys-
tems such as the insulin or transferrin recep-
tor; and active efflux transporters such as
p-glycoprotein and the associated anti-porters.
Studies to determine which strategies are most
effective and how they can be improved for
patients with neurological diseases are encour-
aged. Research areas appropriate for this PAS
include, but are not limited by the following
examples: 1) Develop and characterize in vivo
and in vitro models that reflect the unique
features of the BBB as translational models of
neurological disease. Existing in vivo models,
such as those for stroke or lysosomal storage
diseases, may also prove useful for studying
the structure and dynamics of the BBB.
Studies that validate in vitro results with in
vivo models are encouraged; 2) Examination
of the genes and proteins that are uniquely
expressed by the intact BBB and mechanisms
by which brain cells regulate endothelial cell
gene expression. This includes changes that
occur in response to neurological disease or
the aging process, for example, characteriza-
tion of molecular signatures for disease diag-
nosis and targeting; 3) Explore the genesis and
regulation of the BBB, its stem cell origins
and remodeling of the (diseased/damaged/
aged) brain microvasculature; 4) Identify sig-
nal transduction pathways of brain capillary
endothelial transcytosis and tight junction reg-
ulation under normal and disease conditions;
5) Characterize endogenous influx and efflux
properties of the barriers including trans-
porters in luminal and abluminal membranes
of brain endothelium and epithelium; 6)
Identify regional diversity of barrier properties
within the brain and spinal cord microvascula-
ture; 7) Characterize brain endothelial tight
junction proteins in normal and disease states;
8) Investigate the various enzymatic barrier
mechanisms; 9)Characterize membrane pro-
tein expression by cells of the BBB; 10)
Development of novel brain drug and gene
delivery methods based on unique properties
of the BBB including gene therapy via vectors
or via modified autologous cell transfer; 11)
Explore the molecular basis of microbial inter-
actions with brain endothelium; 12) Develop
neuroimaging tools to identify changes in
BBB permeability in vivo; 13) Examination of
the molecular and cellular mechanisms of
leukocyte migration at the BBB throughout
the lifespan; 14) Comparison of transport
systems in brain endothelia with choroids
plexus epithelium as well as systemic epithelial
cells; 15) Explore the interactions among the
cellular and matrix elements of the BBB, for
example, the microvascular basement mem-
brane; 16) Examine the plasticity of the
blood-brain and blood-CSF interfaces
throughout the lifespan. 
Applications should focus on neurological
disorders relevant to the research missions of
NINDS, the National Institue of Mental
Health (NIMH) and/or the National Institute
on Aging (NIA). A partial list of diseases of
interest to NINDS is given in Appendix A of
the planning document Neuroscience at the
New Millennium; see http://www.ninds.nih.
gov/about_ninds/strategic_plan.htm. 
These include neurological disorders (e.g.
stroke, brain tumors, Parkinson's disease,
brain and spinal cord trauma, epilepsy, multi-
ple sclerosis, brain lysosomal storage disorders,
neuro-AIDS and Alzheimer's disease). The
NIMH is interested in mechanistic studies of
trafficking of cells, immune molecules and
drugs across the blood-brain and blood-csf
barriers during development and adulthood
and how these processes impact the pathogen-
esis of neuroAIDS and mental disorders; see
http://www.nimh.nih.gov/research/nimh-
webs.cfm.
NIA is interested in age-related neurode-
generative disorders, such as Alzheimer's disease,
brain injury, and impairments in cognitive,
motor and sensory functions. Research areas rel-
evant to the mission of the NIA can be found
at: http://www.nia.nih.gov/research/extramural/
neuroscience/programs.htm.
A large amount of basic research is needed
to significantly change how we translate neuro-
science research bidirectionally. This PAS is
focused on stimulating new concepts in the
BBB field through the exploratory/develop-
mental grant (R21) and the R01 mechanisms.
The current workforce in the BBB field is small
relative to the scientific and clinical needs for
improved understanding of the BBB and
progress will require collaboration among cur-
rent investigators and scientists from disciplines
not currently working in this area. Therefore,
training and early career development will be
encouraged (please contact Program Staff for
additional information). This PAS will remain
active for 3 years to address the many gaps in
our knowledge of how the neuroprotective bar-
riers function and the time needed to increase
the workforce in this critically important trans-
lational research area.
As an applicant, you will be solely respon-
sible for planning, directing, and executing
the proposed project. Applicants are encour-
aged to contact program staff for advice about
choosing the appropriate grant mechanism.
The R21 mechanism (see http://
grants.nih.gov/grants/guide/pa-files/PA-03-
107.html) is intended to encourage new
exploratory/developmental research projects
by providing support for the early stages of
their development. For example, such projects
could assess the feasibility of a novel area of
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investigation or a new experimental system
that has the potential to enhance health-relat-
ed research. These studies may involve consid-
erable risk but may lead to a breakthrough in
a particular area, or to the development of
novel techniques, agents, methodologies,
models or applications that could have major
impact on a field of biomedical, behavioral, or
clinical research.
Applications for R21 awards should
describe projects distinct from those support-
ed through the traditional R01 mechanism.
For example, long-term projects, or projects
designed to increase knowledge in a well-
established area will not be considered for R21
awards. Applications submitted under this
mechanism should be exploratory and novel.
These studies should break new ground or
extend previous discoveries toward new direc-
tions or applications. R21 applications may
request a project period of up to two years
with a combined budget for direct costs of up
$275,000 for the two-year period. For exam-
ple, you may request $100,000 in the first
year and $175,000 in the second year. The
request should be tailored to the needs of your
project. Normally, no more than $200,000
may be requested in any single year. 
This PAS uses just-in-time concepts. It
also uses the modular budgeting as well as the
non-modular budgeting formats (see
http://grants.nih.gov/grants/funding/modu-
lar/modular.htm). Specifically, if you are sub-
mitting an application with direct costs in
each year of $250,000 or less, use the modular
budget format. Otherwise follow the instruc-
tions for non-modular budget research grant
applications. This program does not require
cost sharing as defined in the current
NIH Grants Policy Statement at http://
grants.nih.gov/grants/policy/nihgps_2001/
part_i_1.htm.
Competing continuation applications
submitted in response to this PAS will com-
pete with all investigator-initiated applications
and be referred and reviewed according to
the customary peer review procedures.
Responsibility for the planning, direction, and
execution of the proposed project will be sole-
ly that of the applicant. The earliest anticipat-
ed award date is June 1, 2004.
NINDS, NIMH, and NIA have set aside
$2,000,000 in total costs per year, in addition
to funds available for applications sent in
response to this PA that score within the
NINDS payline (see NINDS Funding
Strategy at http://www.ninds.nih.gov/
funding/ninds_funding_strategy.htm),
depending on the overall scientific merit of
the applications and the availability of funds
throughout the duration of this solicitation (3
years). Applications submitted in response to
this PAS will compete with all investigator-ini-
tiated applications for funding. 
The total project period for an application
submitted in response to this PAS may not
exceed 5 years. Because the nature and scope of
the research proposed may vary, it is anticipated
that the size of each award will also vary.
Although the financial plans of the Institute
provide support for this program, awards pur-
suant to this PAS are contingent upon the avail-
ability of funds and the receipt of a sufficient
number of meritorious applications.  
Applications must be prepared using the
PHS 398 research grant application instruc-
tions and forms (rev. 5/2001). Applications
must have a Dun and Bradstreet (D&B) Data
Universal Numbering System (DUNS) num-
ber as the Universal Identifier when applying
for Federal grants or cooperative agreements.
The DUNS number can be obtained by call-
ing (866) 705-5711 or through the web site at
http://www.dunandbradstreet.com. The
DUNS number should be entered on line 11
of the face page of the PHS 398 form. The
PHS 398 is available at http://grants.nih.gov/
grants/funding/phs398/phs398.html in an
interactive format. For further assistance con-
tact GrantsInfo, 301-435-0714, email:
GrantsInfo@nih.gov.
Applications submitted in response to this
PAS will be accepted at the standard applica-
tion deadlines, which are available at
http://grants.nih.gov/grants/dates.htm.
Application deadlines are also indicated in the
PHS 398 application kit. Please note that
AIDS related applications have separate
receipt dates.
Supplemental Instructions: All instruc-
tions for the PHS 398 (rev. 5/2001) must be
followed, with these exceptions: 1) Research
Plan. For R21 applications only, items a – d
of the Research Plan (Specific Aims,
Background and Significance, Preliminary
Studies, and Research Design and Methods)
may not exceed a total of 15 pages. No pre-
liminary data is required for R21 proposals,
but may be included if it is available. Please
note that a Progress Report is not needed for
R21 awards; competing continuation applica-
tions for an exploratory/developmental grant
will not be accepted. 2) Appendix. Use the
instructions for the appendix detailed in the
PHS 398 except that for R21 applications, no
more than 5 manuscripts, previously accepted
for publication, may be included. 
Applications must be received by or
mailed on or before the receipt dates described
at http://grants.nih.gov/grants/funding/sub-
missionschedule.htm. The CSR will not
accept any application in response to this PAS
that is essentially the same as one currently
pending initial review unless the applicant
withdraws the pending application. The CSR
will not accept any application that is essen-
tially the same as one already reviewed. This
does not preclude the submission of a substan-
tial revision of an unfunded version of an
application already reviewed, but such appli-
cation must include an Introduction address-
ing the previous critique.
Contact: Thomas P. Jacobs, NINDS,
Neuroscience Center, Rm 2112, 6001
Executive Blvd, Bethesda, MD 20892-9527
USA, 301-496-1431, fax: 301-480-2424,
email: jacobst@ninds.nih.gov; Jeymohan
Joseph, NIMH, Neuroscience Center, Rm
6202 6001 Executive Blvd, Bethesda, MD
20892-9527 USA, 301-443-3012, fax: 301-
443-9719, email: jjeymoha@mail.nih.gov;
Bradley C. Wise, NIA, 7201 Wisconsin
Avenue, Suite 350, Bethesda, MD 20892-
9205 USA, 301-496-9350, fax: 301-496-
1494, email: wiseb@nia.nih.gov. Reference:
PA No. PAS-03-165 
Interactions Between Stem Cells and the
Microenvironment In Vivo
National Institute of Neurological Disorders
and Stroke (NINDS), the National Institute
on Drug Abuse (NIDA), the National
Institute of Deafness and Other
Communication Disorders (NIDCD) the
National Institute of Alcohol Abuse and
Alcoholism (NIAAA), and the National
Institute on Aging (NIA) invite applications
for studies on the cellular and molecular sig-
naling between the local environment within
organisms and stem and progenitor cells that
are either introduced as transplants or are nor-
mally resident within host tissues and organs.
The objective of this initiative is to promote a
thorough exploration and characterization of
the bi-directional communication between
multipotent cells and the three-dimensional
local milieu or niche that they encounter in
vivo under normal and compromised states,
such as with aging or following injury, disease
or drug exposure. Of particular interest is the
rigorous characterization of how interactions
with localized cues in space and time regulate
stem cell survival, migration, replication and
'plasticity' in the nervous system and other
parts of the body. Projects that address com-
parisons between the responses of stem cells
within niches in the developing and mature or
aging nervous system in vivo, or in host
microenvironments modified by injury, dis-
ease, or by exposure to drugs and alcohol
would also be directly relevant to this Program
Announcement with Set-aside (PAS), as are
studies to compare different classes of stem
cells or progeny at progressively more
advanced stages of differentiation when placed
in the same sites in vivo.
Unlike organs such as the skin and the gut
that self-renew throughout life, the nervous sys-
tem in adult mammals is restricted in its ability
to replace neurons and glia that have been lost
through injury, disease, alcohol and drug abuse
or even advancing age.  Stem cell research offers
enormous potential for treating many congeni-
tal, developmental, psychiatric or degenerative
diseases of the nervous system for which there
are no treatments or cures. Under the appropri-
ate tissue culture conditions, a variety of multi-
potent cells appear to acquire many properties
of neurons and glia – a first step toward devel-
oping cell replacement therapies for neurologi-
cal dysfunction. The discovery of endogenous
stem cells, residing either within the nervous
system or in other tissues raises the possibility
that these intrinsic systems may be harnessed to
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restore defective cells and functions. In both
cases the expectation is that, when exposed to
the optimal microenvironment in vivo, endoge-
nous or transplanted stem cells will differentiate
in a manner appropriate to the local brain
region, and integrate with the existing circuits
in the nervous system. The past decade has seen
enormous progress in our understanding of the
specific requirements of stem cells to proliferate
and differentiate along specified lineages. This
progress has been made possible by the discov-
ery of a myriad of growth factors and substrate
conditions followed by careful testing in cul-
ture. Unfortunately, the behavior of cells in tis-
sue culture does not adequately predict how
these same cells will behave when transplanted
into the living host where multiple known and
unknown factors converge to influence the bio-
logical process. We do not know the whole
spectrum of factors present in vivo that influ-
ence cell fate. Effective use of stem and prog-
enitor cells for therapeutic purposes hinges on
their ability to thrive, integrate, and function
in a biologically meaningful manner in vivo
without causing adverse events. Therefore the
next stage in developing cell restoration thera-
py requires understanding how the newly gen-
erated cells will behave within the host. 
Recent reports indicate that the “niche” or
local microenvironment that a stem cell
encounters governs its behavior and fate. For
example, adult neural stem cells produced
neurons when transplanted into the neuro-
genic zone of the hippocampus, but produced
astrocytes in the environment of the spinal
cord. Further investigation showed that a spe-
cific component of the local environment, the
regional astrocytes from the hippocampus
were capable of instructing these stem cells to
adopt a neuronal fate in vitro. In addition to
regional differences within the nervous sys-
tem, the microenvironment encountered by a
stem cell may vary as a function of age of the
host organism. Similarly, alteration of the
niche by injury, drugs or other circumstances
is likely to affect the ability of transplanted
stem cells to survive, differentiate and
integrate into existing neural circuitry.
Understanding these changes will be impor-
tant in making decisions about the use of cell
replacement therapies in very young or elderly
patients, in patients with a history of alcohol
or drug usage, or suffering from injury or
other neurological conditions. 
Transplanted cells can act to influence
and change host cells in their vicinity. Stem
cells may release agents that alter the activity
or resiliency of damaged host cells. These
dynamic interactions are inevitable as living
cells and tissue contact, react and respond to
each other in time and space. Teasing out and
understanding these interactions poses a major
challenge that must be faced in order to devel-
op realistic cell replacement therapies and
enhance normal tissue regeneration. 
This PAS is intended to promote studies
that establish and identify the nature and
action of microenvironmental cues in the
nervous system that regulate stem cell fate. It
specifically targets cellular, molecular and
genetic mechanisms that act in vivo to influ-
ence stem cell survival, homing/migration,
adhesion, differentiation, plasticity and
tumorigenicity in both the central and periph-
eral nervous systems. Applications that only
propose in vitro studies will not be responsive
to this initiative.
The following examples illustrate areas that
are of high interest; other innovative projects
are also encouraged. These examples of research
approaches are not meant to be all-inclusive or
restrictive. Plans for data and/or reagent sharing
and promulgation of results will be integral to
the applications. 1) Identification, localization
and comparison of known or novel cues within
the developing, adult and aging nervous system
that influence the mitotic potential, cell cycle
and differentiation of stem and progenitor cells
along specific lineages; 2) Characterization of
the cell-extrinsic and cell-intrinsic signaling
pathways and components involved in trans-
ducing the action of local cues on stem and
progenitor cells in vivo; 3) Investigation of the
causal relationship between site-specific changes
of endogenous cues resulting from injury, dis-
ease, exposure to alcohol, drugs of treatment or
abuse, and any resulting alterations of stem cell
activity; 4) Evaluation of the effects of external
factors such as stress, exercise, or an enriched
versus impoverished living conditions on the
microenvironment within the host organism,
and how these changes in microenvironment
influence the behavior of stem cells at different
periods throughout the life span of the organ-
ism; 5) Investigation of local cellular interac-
tions that determine and maintain the
structural and functional integration of prog-
enitor cells into the host nervous system and
existing circuitry; 6) Development of assays
facilitating the discovery of novel endogenous
signals that modulate stem cell behavior and
fate, as well as signals generated by stem cells
that regulate components of the local host tis-
sue. These may include the development of
measures (physiological, behavioral, neuro-
chemical, imaging) to evaluate the integration
and function of progenitor cells in the devel-
oping, adult and aging nervous system; 7)
Assessment of the short and long-term local
effects of the interactions between the
immune system and glial reactions gendered
in response to the infiltration of stem cells and
their progeny in the host.
The NIDA is interested in how drugs of
abuse and factors such as stress andenviron-
ment affect the behavior of stem cells and the
functional consequences of such alterations,
which might be related to the cognitive
impairments, developmental deficits, neuroad-
aption and addictive behaviors seen in drug
abuse. The NIDCD is particularly interested
in stem cell research targeting the various
peripheral components of the auditory (hear-
ing), olfaction (smell) and gustatory (taste)
systems. The NIAAA is interested in how
alcohol exposure alters the biochemical
environment of tissues, thus interfering with
the capacity of stem cells to establish contact,
differentiate and function in target tissue. The
NIA is interested in stem cell research and
neurogenesis in the aging nervous system with
emphasis on basic neurobiology, motor and
sensory systems, integrative neurobiology,
cognition and the dementias of aging, particu-
larly Alzheimer's disease. 
This PAS will use the NIH Exploratory/
Developmental Grant (R21) and the Research
Project Grant (R01) award mechanisms. As an
applicant, you will be solely responsible for
planning, directing, and executing the pro-
posed project. The proposed project period
during which the research will be conducted
should adequately reflect the time required to
accomplish the stated goals and should be no
more than 5 years for R01 grants. The R21
grants are one-time awards to support innova-
tive, high impact research projects that would
either 1) generate pilot data to assess the feasi-
bility of a novel avenue of investigation, 2)
involve high risk experiments that could lead
to a breakthrough in a particular field, or 3)
demonstrate the feasibility of new technolo-
gies that could have major impact in a specific
area. Support for the R21 grants is limited to
two years with a cumulative maximum of
$275,000 direct costs requested for both
years. This program is appropriate both for
new investigators seeking to establish indepen-
dent research careers and for established inves-
tigators wishing to explore new areas of
neuroscience or develop novel technologies.
For further information on the R21 mecha-
nism, including Institute-specific information,
see http://grants.nih.gov/grants/guide/pa-
files/PA-03-107.html.
This PAS uses just-in-time concepts. It
also uses the modular as well as the non-mod-
ular budgeting formats; see http://grants.nih.
gov/grants/funding/modular/modular.htm.
Specifically, if you are submitting an applica-
tion with direct costs in each year of $250,000
or less, use the modular format. Otherwise
follow the instructions for non-modular
research grant applications. This program does
not require cost sharing as defined in the cur-
rent NIH Grants Policy Statement at http://
grants.nih.gov/grants/policy/nihgps_2001/
part_i_1.htm. 
The participating ICs have set aside a total
of $2 million dollars per year to support this
initiative. The amount and timing of awards
paid from set aside funds will depend on the
overall scientific merit of the applications and
the availability of funds throughout the dura-
tion of this solicitation (2 years). Because the
nature and scope of the proposed research will
vary from application to application, it is
anticipated that the size and duration of each
award will also vary. Although the financial
plans of the IC(s) provide support for this pro-
gram, awards pursuant to this PAS are contin-
gent upon the availability of funds and the
receipt of a sufficient number of meritorious
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Upon initiation of the program, the par-
ticipating institutes will sponsor an annual
meeting to encourage the exchange of infor-
mation among investigators who participate in
this program. In the preparation of the budget
for the grant application, applicants should
REQUEST ADDITIONAL TRAVEL
FUNDS for one meeting each year to be held
in Bethesda, Maryland. Applicants should also
include a statement in the applications indi-
cating their willingness to participate in such
meetings. Applicants are also strongly encour-
aged to include plans for data and/or reagent
sharing and promulgation of results. 
Applications must be prepared using the
PHS 398 research grant application instruc-
tions and forms (rev. 5/2001). Applications
must have a Dun and Bradstreet (D&B) Data
Universal Numbering System (DUNS) num-
ber as the Universal Identifier when applying
for Federal grants or cooperative agreements.
The DUNS number can be obtained by call-
ing (866) 705-5711 or through the web site at
http://www.dunandbradstreet.com/. The
DUNS number should be entered on line 11
of the face page of the PHS 398 form. The
PHS 398 is available at http://grants.nih.gov/
grants/funding/phs398/phs398.html in an
interactive format. For further assistance con-
tact GrantsInfo, 301-435-0714, email:
GrantsInfo@nih.gov.
Applications submitted in response to this
PAS will be accepted at the standard applica-
tion deadlines, which are available at http://
grants.nih.gov/grants/dates.htm. Application
deadlines are also indicated in the PHS 398
application kit.
Applications must be mailed on or before
the receipt dates described at http://
grants.nih.gov/grants/funding/submission-
schedule.htm. The CSR will not accept any
application in response to this PAS that is
essentially the same as one currently pending
initial review unless the applicant withdraws
the pending application. The CSR will not
accept any application that is essentially the
same as one already reviewed. This does not
preclude the submission of a substantial revi-
sion of an unfunded version of an application
already reviewed, but such application must
include an Introduction addressing the previ-
ous critique.
Contact: Arlene Y. Chiu, Program
Director, Repair and Plasticity Program,
NINDS, Neuroscience Center, Room 2207,
MSC 9525, Bethesda, MD 20892-9525 USA,
301-496-1447, fax: 301-480-1080, email:
chiua@ninds.nih.gov; Geraline C. Lin,
Division of Neuroscience and Behavioral
Research, National Institute on Drug Abuse,
6001 Executive Blvd, Room 4282, MSC
9555, Bethesda, MD 20892-9555 USA, 301-
435-1305, fax: 301-594-6043, email:
glin@nida.nih.gov; Barry Davis, Director,
Taste and Smell Program, NIDCD, 6120
Executive Blvd, Room 400-C, MSC-7180,
Rockville, MD 20892-7180 USA, 301-402-
3464; fax: 301-402-6251 email:
davisb1@nidcd.nih.gov; Sam Zakhari,
Director, Division of Basic Research, NIAAA,
6000 Executive Blvd, Suite 402, MSC 7003,
Bethesda, MD 20892-7003 USA, 301-443-
0799, fax: 301-594-0673, email:
sz14w@nih.gov; Bradley C. Wise, Program
Director, Fundamental Neuroscience,
Neuroscience and Neuropsychology of Aging
Program, NIA, 7201 Wisconsin Ave, Suite
350 MSC 9205, Bethesda, MD 20892-9205
USA, 301-496-9350, fax: 301-496-1494,
email: wiseb@nia.nih.gov. Reference: PA No.
PAS-03-172 
Metabolomics Technology Development   
The Institutes and Centers of the National
Institutes of Health (NIH) invite applications
for development and application of new tech-
nologies in metabolomics to enable research
aimed at elucidating biological pathways and
networks. The purpose of this initiative is to
encourage the development of highly innova-
tive and sensitive tools for identifying and
quantifying cellular metabolites and their flux-
es at high anatomical, spatial, and temporal
resolution. The general aim of metabolomics is
to identify, measure and interpret the complex
time-related concentration, activity and flux of
endogenous metabolites in cells, tissues, and
other biosamples such as blood, urine, and
saliva. For the purposes of this solicitation,
metabolites include small molecules that are
the products and intermediates of metabolism,
but also carbohydrates, peptides, and lipids.
The need for innovative technologies for mea-
suring and quantifying metabolites involved
in cellular pathways and networks was articu-
lated in the 2003 NIH Roadmapping
Initiative. It is expected that the technologies
developed under this initiative will play a
major role in transferring capabilities to labo-
ratories and research institutes that are investi-
gating the underlying pathways involved in
cellular homeostasis, perturbation, develop-
ment, and aging. Many ongoing research pro-
grams focus on development of new genomics
and proteomics tools and utilization of those
approaches for studying cellular function. In
contrast, relatively few research programs
focus on metabolomics technology develop-
ment and application. This initiative is to
encourage the development of highly innova-
tive and sensitive tools for identifying and
quantifying cellular metabolites and their flux-
es at high anatomical resolution—extending
to subcellular—and at a temporal resolution
that would be appropriate to understanding
cellular processes at biologically relevant
timescales. The scope of projects that would
be appropriate ranges from techniques for
improving and refining the process of sample
separation and processing; to new methods,
reagents or instrumentation for identifying
and measuring metabolites and their fluxes; to
the development and utilization of data reduc-
tion, management, and analysis tools needed
to establish proof of principle for the technol-
ogy. New technologies that, if successful, have
the potential to be scalable, either as high-
throughput applications or as advances that
would be used in a large number of laborato-
ries, are especially encouraged. While it is also
important to develop data storage, data min-
ing, and pathway modeling capabilities for
metabolomics, these issues are explicitly not
included in this particular solicitation.
Metabolomics presents unique challenges
for sample collection and extraction and for
determining analyte identity, concentration,
structure, activity and flux in cells. The cellu-
lar metabolome is complex, involving several
compound classes of small molecules (pep-
tides, lipids, amino acids, carbohydrates) that
vary in subunit concentration, size, structure,
polarity, and functional groups. Technologies
currently in use for metabolomic analysis
include NMR, chromatography and mass
spectrometry, each of which has significant
limitations in quantification, scope, and/or
throughput. No one technology can effective-
ly measure, identify and quantify, with suffi-
cient sensitivity and precision, the diverse
range of metabolites and their dynamic fluctu-
ations in cells. An integrated set of technolo-
gies is needed to address the entire spectrum
of challenges for metabolomics. Ideally, new
technologies should yield quantitative, com-
prehensive data and be applicable to achieving
anatomical resolution at the cellular and sub-
cellular level. 
This initiative seeks to encourage technol-
ogy developments to address three interrelated
components of metabolomics: (1) sample col-
lection, extraction, recovery and validation for
specific classes of metabolites; (2) analyte
detection, identification, quantification, and
structure elucidation; and (3) and data man-
agement, reduction and analysis. Specific areas
of research emphasis include approaches to
address the large dynamic range of metabolite
concentration in biological samples, the com-
plexity of metabolite mixtures, the inherent
noise of the metabolite profile, the vast num-
ber of unidentified compounds present within
single samples, and the rapidly changing tem-
poral and spatial variability (flux) of the cell's
metabolite complement. It is imperative that
new technology incorporate approaches for
data management, reduction and analysis to
support the technology development. This
initiative encourages applications that seek to
improve existing technologies, including scal-
ing up to high throughput application, as well
as those that seek to develop new approaches
that have the potential for measuring entire
cellular metabolomes or subsets (e.g., amino
acid derivatives, peptide derivatives) whose
analysis provides enabling technologies,
including appropriate tools for data reduction
and analysis. 
Applications will be evaluated for the
potential of the proposed activities to address
all three components of metabolomics that are
listed above. However, it is anticipated that
these components, collectively, might be too
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three comprehensively. Accordingly, applica-
tions may focus on any of the components of
metabolomics listed above and may propose
single or multiple technologies. Investigators
will be expected to clearly define the scope of
their activities, and to justify why the specific
type(s) of data that the technologies will
address are likely to be important to under-
standing cellular pathways and networks. This
initiative encourages applications involving
multi-disciplinary teams representing self-
assembled groups of collaborating investiga-
tors, at one or several sites, with specific
expertise in metabolomics technology as well
as data management and statistical approaches
relevant to the proposed technology.
Partnerships between academia and industry
are encouraged, to facilitate technology trans-
fer and capacity building at academic institu-
tions. This solicitation seeks to encourage
highly innovative and potentially risky
approaches. However, it is likely that some
proposed technologies will be more mature, at
the onset, than others. Accordingly, this RFA
will use the NIH Phased Innovation
(R21/R33) and Exploratory/Development
Research Grant Phase 2 (R33) award mecha-
nisms. Applicants may submit a combined
R21/R33 application, or a stand-alone R33
application if technological feasibility can be
documented at the time of submission.
Applicants may request up to three years of
funding, either using the R33 mechanism for
the entire time, or via a phased format that
begins as an R21 award and transitions to an
R33 award. The duration of the R21 phase
may be either one year or two years. A grant
may be considered for renewal or supplemen-
tation after the three year period of support if
it is obvious that a newly developed technolo-
gy will have exceptionally high impact on the
field, but additional time is required to opti-
mize it. Applicants for a phased award cannot
request more than $800,000 in direct costs
per year of the R21 phase. Applicants may not
request more than $1.5 million in direct costs
per year of the R33 phase, or per year of the
entire award if it is solely R33. It is empha-
sized that the figures above are a maximum.
We envisage that a range of activities could be
appropriate for this solicitation, from an indi-
vidual well-focused goal, to a set of closely
related or well-integrated technology develop-
ment aims. The R21 award mechanism sup-
ports innovative, high-risk/high-impact
research requiring preliminary testing or
development; exploration of the use of
approaches and concepts new to a specific
substantive area; or research and development
of new technologies, techniques, or methods. 
Applications will be considered high-
impact if they demonstrate the potential for
ground-breaking significance, and high-risk
because they either lack sufficient preliminary
data to ensure their feasibility, or propose use
of a new model or a unique system. Eligibility
for transition to the R33 phase will be based
on successful completion of the negotiated
milestones, which must be specified in the
application, and programmatic review. The
objective of the R33 phase is continuation of
innovative exploratory and developmental
research initiated during the R21 mechanism.
Research conducted in the R33 phase will
focus on demonstrating proof of principle for
application of the technology to elucidate
functional components and interactions of
metabolites within biological pathways and
networks. While the intent of the R21 award
is to encourage the development of highly
innovative technologies, the potential for the
proposed technology to advance our under-
standing of biological pathways and networks
will be an important criterion for evaluating
the R33 phase of an application or the entire
application, if it is for a stand—alone R33
award. Development of complex, integrated
technologies for metabolomics problems will
require a context within which methods devel-
opment can proceed. Accordingly, investiga-
tors should select a model system, defined at
the cellular or subcellular level, to serve as a
framework for demonstrating the technologi-
cal capabilities of the resource. 
This RFA will use the NIH Phased
Innovation (R21/R33) and Exploratory/
Development Research Grant Phase 2 (R33)
award mechanisms. As an applicant you will be
solely responsible for planning, directing, and
executing the proposed project. This RFA is a
one-time solicitation. Future unsolicited, com-
peting-continuation applications based on this
project will compete with all investigator-initi-
ated applications and will be reviewed accord-
ing to the customary peer review procedures.
The anticipated award date is September 30,
2004. Applications that are not funded in the
competition described in this RFA may be
resubmitted as NEW investigator-initiated
applications using the standard receipt dates
for NEW applications described in the instruc-
tions to the PHS 398 application.
This RFA uses just-in-time concepts. It
also uses the non-modular budgeting format.
Please follow the instructions for non-modular
budget research grant applications. This pro-
gram does not require cost sharing as defined
in the current NIH Grants Policy Statement
at http://grants.nih.gov/grants/policy/nihg-
ps_2001/part_i_1.htm. 
Prospective applicants are asked to submit
a letter of intent that includes the following
information: 1) Descriptive title of the pro-
posed research, 2) Name, address, and tele-
phone number of the Principal Investigator,
3) Names of other key personnel, 4)
Participating institutions, 5) Number and title
of this RFA. 
Applications must be prepared using the
PHS 398 research grant application instruc-
tions and forms (rev. 5/2001). Applications
must have a DUN and Bradstreet (D&B)
Data Universal Numbering System (DUNS)
number as the Universal Identifier when
applying for Federal grants or cooperative
agreements. The DUNS number can be
obtained by calling (866) 705-5711 or
through the web site at http://www.dunand-
bradstreet.com/. The DUNS number should
be entered on line 11 of the face page of the
PHS 398 form. The PHS 398 document is
available at http://grants.nih.gov/grants/
funding/phs398/phs398.html in an interactive
format. For further assistance contact
GrantsInfo, 301-435-0714, email:
GrantsInfo@nih.gov.
The RFA label available in the PHS 398
(rev. 5/2001) application form must be affixed
to the bottom of the face page of the applica-
tion. Type the RFA number on the label.
Failure to use this label could result in delayed
processing of the application such that it may
not reach the review committee in time for
review. In addition, the RFA title and number
must be typed on line 2 of the face page of the
application form and the YES box must be
marked. The RFA label is also available at:
http://grants.nih.gov/grants/funding/phs398/
labels.pdf.
Applications must be received on or
before the application receipt date listed in the
heading of this RFA. If an application is
received after that date, it will be returned to
the applicant without review. 
The Center for Scientific Review (CSR)
will not accept any application in response to
this RFA that is essentially the same as one
currently pending initial review, unless the
applicant withdraws the pending application.
However, when a previously unfunded appli-
cation, originally submitted as an investigator-
initiated application, is to be submitted in
response to an RFA, it is to be prepared as a
NEW application. That is, the application for
the RFA must not include an Introduction
describing the changes and improvements
made, and the text must not be marked to
indicate the changes from the previous
unfunded version of the application. 
Letter of Intent Receipt Date: February
24, 2004; Application Receipt Date: March
24, 2004; Peer Review Date: June/July 2004;
Council Review: September 2004; Earliest
Anticipated Start Date: September 30, 2004.
Contact: Maren R. Laughlin, Division of
Diabetes, Endocrinology and Metabolism,
NIDDK, 6707 Democracy Blvd, Room
6101, MSC 5460, Bethesda, MD 20892-
5460 USA, 301-594-8802, fax: 301-480-
3503, email: laughlinm@extra.niddk.nih.gov;
Maren R. Laughlin, Division of Diabetes,
Endocrinology and Metabolism, NIDDK,
6707 Democracy Blvd, Room 6101, MSC
5460, Bethesda, MD 20892-5460 USA, 301-
594-8802, fax: 301-480-3503, email: laugh-
linm@extra.niddk.nih.gov. Reference: RFA
No. RFA-DK-04-001
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